Global Large Volume Wearable Injectors Market 2017-2027 with Emphasis on the Emergence of Such Patient-Centric, Convenient, Cost-Effective and User-Friendly Wearable Injectors - Research and Markets

News provided by

Mar 03, 2017, 05:15 ET

DUBLIN, Mar 03, 2017 /PRNewswire/ --

Research and Markets has announced the addition of the "Large Volume Wearable Injectors Market (3rd Edition), 2017-2027" report to their offering.

The "Large Volume Wearable Injectors Market (3rd Edition), 2017-2027" report features an extensive study of the current landscape and the likely future evolution of this category of drug delivery devices over the next ten years. With the increasing incidence of chronic and lifestyle-related diseases across the globe, the demand for efficient drug delivery systems is growing at a rapid pace.

It is worth noting that the VC community has demonstrated significant interest in funding projects related to such wearable injectors. These investments are expected to drive further innovation and lead to the introduction of novel device candidates in the industry. Quite recently, in January 2017, scPharmaceuticals closed a series B investment round worth USD 45.6 million.

The company intends to use the funding to bring Furoscix and the sc2Wear Infusor to the market in the US. Earlier, in July 2016, SteadyMed Therapeutics raised USD 32 million in a private placement round financed by Deerfield Capital Management, Federated Investors and OrbiMed. In September 2015, CeQur completed a USD 100 million Venture (Series C) financing round, which was led by Woodford Investment Management, Arthurian Life Sciences, Endeavour Vision, VI Partners and Schroders.

In order to simplify the process of drug delivery, eliminate costs and reduce the incidence of needlestick injuries, the pharmaceutical industry has shifted its focus towards the development of self-injection devices for parenteral drugs/therapies.

This report specifically lays emphasis on the emergence of such patient-centric, convenient, cost-effective and user-friendly wearable injectors that are capable of administering large volumes of a drug subcutaneously in a home-care setting.

It is worth noting that the concept behind such injectors is being widely employed for the delivery of insulin. Over 15 such unique series of injectors (excluding variants) have already entered the market. On the other hand, there is only one large volume wearable injector (mentioned above) approved for the administration of a non-insulin biologic in the US.

However, with a variety of biologics under investigation, we believe that device developers have a significant opportunity waiting to be tapped. The field is likely to pick up momentum in the next few years. In fact, an increase in the partnerships and investment activities demonstrate that the market is geared towards significant growth in the mid to long term.

One of the key objectives outlined for the study was to evaluate the future potential of the ongoing development programs of both big and small firms.

Key Topics Covered:

1. Preface

2. Executive Summary

3. Introduction

4. Large Volume Wearable Injectors: Market Landscape

5. Product Competitiveness, Clinical Design And Patent Analysis

6. Large Volume Wearable Injectors For Non-Insulin Biologics: Device Profiles

7. Large Volume Wearable Injectors For Insulin: Device Profiles

8. Case Studies: Drug-Device Combinations Under Evaluation

9. Target Biologics For Large Volume Wearable Injectors

10. Market Forecast And Opportunity Analysis

11. Large Volume Wearable Injectors: Key Players

12. Swot Analysis

13. Conclusion

14. Interview Transcripts

15. Appendix 1: Tabulated Data

16. Appendix 2: List Of Companies And Organizations

5AM Ventures
ARTORG Center for Biomedical Research
AVEO Oncology
AbGenomics
AbbVie
Abbott Laboratories
Ablynx
Acceleron Pharma
Accord Healthcare
Aduro Biotech
Advaxis
Agenus
AgonOx
Akorn
Alder BioPharmaceuticals
Alexion Pharmaceuticals
Alixinox Pharmaceuticals
Alnylam Pharmaceuticals
AlphaCore Pharma
Altor BioScience
Alzheimer's Association
American Academy of Neurology
American Nurses Association
Amgen
Amphastar Pharmaceuticals
Animas Corporation
Antares Pharma
Antigen Express
Apotex
Arbutus Biopharma
Argos Therapeutics
Arteaus Therapeutics
Arthurian Life Sciences
Asante Solutions
Aspen Pharmacare
Astellas Pharma
Asthma and Allergy Foundation of America
AstraZeneca
Athersys
Aurum Pharmaceuticals
Banque
Bar Ilan University
Bardy Diagnostics
Baxter
Bayer
Bayhill Therapeutics
Becton Dickinson
Bern University Hospital
Bespak
Bigfoot Biomedical
Bio-Path Holdings
BioArctic Neuroscience
BioCSL
BioInvent International
BioMarin Pharmaceutical
Biogen
Bioject Medical Technologies
Biotest
Boehringer Ingelheim
Bristol-Myers Squibb
CANÈ
CEL-SCI Corporation
CONNECT
CROSSJECT
CSL Behring
Cala Health
Calando Pharmaceuticals
Cam Med
Canadian Institute for Health Information
Canadian Intellectual Property Office
Cancer Advances
Cardiome Pharma
Catalyst Biosciences
CeQur
Celgene
Celldex Therapeutics
Cellerant Therapeutics
Cellnovo
Centers for Disease Control and Prevention
Chugai Pharmaceutical
Cincinnati Children's Hospital Medical Center
Cipla
Circadian Technologies
Cleveland BioLabs
Consort Medical
Crealta Pharmaceuticals
CureTech
CytoDyn
Cytonet
DEKA
Daikyo Seiko
Debiotech
Deerfield Management Company
Dekkun
Denderon
Dexcom
Diamyd Medical
Diasend
Duke University Medical Center
EMD Serono
Egalet Corporation
Eisai
Elan Pharmaceuticals
Elcam Drug Delivery Devices
Eli Lilly
Elias Group
Elusys Therapeutics
Emcure Pharmaceuticals
Emergent BioSolutions
Emory University Hospital
Enable Injections
Endeavour Vision
Endo Pharmaceuticals
Endocyte
Eternity Healthcare
European Agency of Occupational Safety and Health
European Pharma Group
Federated Investors
Ferring Pharmaceuticals
FibroGen
Finox Biotech
Five Prime Therapeutics
Flex (formerly Flextronix)
Flowonix Medical
Forma Medical Device Design
Fresenius Kabi
Galaxy Biotech
Galena Biopharma
Genentech
Generon Corporation (Shanghai)
Geno Pharmaceuticals
Genzyme Corporation
Gilead Sciences
Gland Pharma
GlaxoSmithKline
Gliknik
Glooko
Halozyme Therapeutics
HanAll BioPharma
Hanmi Pharmaceutical
HealthPrize Technologies
Heart Failure Clinical Research Network
Heart Failure Society of America
Hemispherx Biopharma
Hospira
INJEX Pharma
IP Holdings
iSense CGM
ImClone Systems
Immatics Biotechnologies
Immune Response BioPharma
ImmunoFrontier
ImmunoGen
Immunocore
Immunomedics
Immunotope
Immunovaccine
Immunovative Therapies
Ind-Swift
Ingenus Pharmaceuticals
Inovio Pharmaceuticals
Insulet Corporation
Insuline Medical
International Diabetes Federation
Ionis Pharmaceuticals
Ipca Laboratories
Ipsen
Janssen Biotech
Johnson & Johnson
KB Partners
KaloBios Pharmaceuticals
Kaléo
Kyowa Hakko Kirin
Leading Pharma
LifeScan
Lundbeckfonden Ventures
MEDAXOR
MENTRIK Biotech
MabVax Therapeutics
MacroGenics
Massachusetts General Hospital
Mayo Clinic
MedImmune
Medical International Technology
Medicom Innovation Partner
Medicus Engineering
Medimop Medical Projects
Medipacs
Medtronic
Medtrum
Merck
Meridian Medical Technologies
Merrimack Pharmaceuticals
Merz Pharma
MetroHealth System
Mode AGC
Modi Mundi Pharma
MolMed
MorphoSys
Morphotek
Mylan
National Institute for Clinical Excellence
National Institutes of Health
Neogenix Oncology
Neon Laboratories
NeuroDerm
Noble
Norwich Pharmaceuticals
Novartis
Novo Nordisk
Nuron Biotech
ORI Healthcare Fund
Occupational Safety and Health Administration
Octapharma
Omeros
OncoGenex Pharmaceuticals
OncoMed Pharmaceuticals
OncoPep
Optimer Pharmaceuticals
OrbiMed
Otsuka Pharmaceutical
Owen Mumford
Peregrine Pharmaceuticals
Perqflo
Pfizer
PharmaJet
PhaseBio Pharmaceuticals
Pico Life Technologies
PicoSulin
Pique Therapeutics
Pliva
Pluristem Therapeutics
Polaris Pharmaceuticals
Polynoma
Portola Pharmaceuticals
Prachi Pharmaceuticals
Progenics Pharmaceuticals
Promethera Biosciences
Prometheus Laboratories
Protalix BioTherapeutics
Qualitest Pharmaceuticals
Quest Pharmatech
Quintessence Biosciences
RAD BioMed
rEVO Biologics
Ranbaxy Laboratories
Ratio Drug Delivery
Regeneron Pharmaceuticals
Roche
Roehr Products
Roxane Laboratories
SBIR Healthcare
SOOIL
STMicroelectronics
Sagent Pharmaceuticals
Salix Pharmaceuticals
Samson Ventures Partners
Sandoz
Sangamo BioSciences
Sanofi
Sarpeta Therapeutics
ScPharmaceuticals
Schroders
SciGen
Seattle Genetics
Sensile Medical
Shionogi
Shire
Sigma-Tau Pharmaceuticals
SillaJen BioTherapeutics
SteadyMed Therapeutics
Stemline Therapeutics
Sun Pharmaceutical Industries
Sunovion Pharmaceuticals
Syntax Corporation
TG Therapeutics
TRACON Pharmaceuticals
TaiMed Biologics
Takeda Pharmaceutical Company
Tamir Biotechnology
Tandem Diabetes Care
Teva Pharmaceutical Industries
The Tech Group
Tidepool
Touche Medical
TypeZero Technologies
UCB
US WorldMeds
Unilife Corporation
United Biomedical
United States Patent and Trademark Office
United Therapeutics
University of Bern
VBL Therapeutics
VI Partners
Vaccinex
Vaccinogen
Valeritas
Valtronic
ViCentra
Vintage Pharmaceuticals
West Pharmaceutical Services
Wockhardt
Woodford Investment Management
World Intellectual Property Organization
XBiotech
XOMA Corporation
Xencor
YOFimeter
Ypsomed

For more information about this report visit http://www.researchandmarkets.com/research/4ccrs6/large_volume

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets